GBCS (Selectis Health) Cash Conversion Cycle: -71.29 (As of Mar. 2026)


GBCS Selectis Health Inc GBCS
45 GF Score
Price $5.21
GF Value $2.14
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Selectis Health Cash Conversion Cycle?

Selectis Health GBCS 45 Cash Conversion Cycle is -71.29 as of Mar. 2026. GuruFocus rates GBCS with a GF Score™ of 45/100 and a GF Value™ of $2.14 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Selectis Health's Days Sales Outstanding for the three months ended in Mar. 2026 was 29.84.
Selectis Health's Days Inventory for the three months ended in Mar. 2026 was 0.
Selectis Health's Days Payable for the three months ended in Mar. 2026 was 101.13.
Therefore, Selectis Health's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2026 was -71.29.


Selectis Health  (OTCPK:GBCS) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Selectis Health Cash Conversion Cycle Related Terms


Selectis Health Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for Selectis Health's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Selectis Health Cash Conversion Cycle Chart

Selectis Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.78 -17.72 -30.43 -54.10 -52.37

Selectis Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -58.96 -63.93 -54.90 -62.09 -71.29

GBCS vs CCM, BMGL, AMS: Cash Conversion Cycle Comparison

For the Medical Care Facilities subindustry, Selectis Health's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Selectis Health Cash Conversion Cycle vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Selectis Health's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Selectis Health's Cash Conversion Cycle falls into.


GBCS
45GF Score
Selectis Health Inc GBCS
Cash Conversion Cycle is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Selectis Health Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Selectis Health's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=21.55+0-73.92
=-52.37

Selectis Health's Cash Conversion Cycle for the quarter that ended in Mar. 2026 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=29.84+0-101.13
=-71.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of -71.29 mean?
Selectis Health (GBCS) has a Cash Conversion Cycle of -71.29 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Selectis Health and its competitors.
Is Selectis Health's Cash Conversion Cycle too high?
Selectis Health's current Cash Conversion Cycle is -71.29. Overall, Selectis Health has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Selectis Health's Cash Conversion Cycle compare to CCM and BMGL?
Selectis Health's Cash Conversion Cycle of -71.29 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 18.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 18.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Selectis Health and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 18.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selectis Health's current Cash Conversion Cycle is -71.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selectis Health stock overvalued right now?
Based on GuruFocus' analysis, Selectis Health (GBCS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.14, compared to a current price of $5.21 — trading 143.5% above its estimated fair value. The current Cash Conversion Cycle is -71.29. Selectis Health's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Selectis Health (GBCS), the current Cash Conversion Cycle is -71.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Selectis Health (GBCS) Overvalued in 2026?

Based on GuruFocus' analysis, Selectis Health stock appears to be overvalued. The current stock price of $5.21 is trading 143.5% above its estimated GF Value™ of $2.14. GuruFocus considers Selectis Health to be Significantly Overvalued.

Key valuation signals for GBCS:

  • Cash Conversion Cycle: -71.29
  • GF Value™: $2.14 vs. price of $5.21 (143.5% above fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the GBCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Selectis Health Business Description

Address 600 17th Street, Suite 284, Denver, CO, USA, 80202
Selectis Health Inc owns and operates medical care facilities in the healthcare industry. The company acquires, develops, leases, and manages healthcare real estate and provides healthcare operations through its wholly-owned subsidiaries. The portfolio is comprised of investments in the following healthcare operations: (i) senior housing (including independent and assisted living) and (ii) post-acute/skilled nursing. It makes investments within the healthcare operations using the following six investment products: (i) direct ownership of properties, (ii) debt investments, (iii) developments and redevelopments, (iv) investment management, (v) the Housing and Economic Recovery Act of 2008, which represents investments in senior housing operations, and (vi) owning healthcare operations.
45GF Score

Get the complete analysis for GBCS

Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.21
Price
$2.14
GF Value